日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer

整合多组学分析鉴定出 BRD8/EP400 是介导 HR+/HER2+ 乳腺癌抗 HER2 反应的关键染色质模块

Gao, Ang; Khatri, Parth H; Ma, Gui; Liu, Peng; Fernandez-Martinez, Aranzazu; Donahue, Kristine; Wang, Yidan; Kim, Eui-Jun; Hu, Mingshan; Liu, Fabao; Zhou, Jingjing; Chan, Ngai Ting; Yang, Xingjian; Welch Schwartz, Rene; Ong, Irene M; Burkard, Mark E; Wisinski, Kari B; Perou, Charles M; Dinh, Huy Q; Xu, Wei

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

奈拉替尼治疗ERBB2突变型肺腺癌的疗效:两项国际II期研究的结果

Li, Bob T; Gandhi, Leena; Ravichandran, Vignesh; Besse, Benjamin; Mazières, Julien; Shapiro, Geoffrey I; Boni, Valentina; Waqar, Saiama N; Park, Haeseong; Quinn, David I; Martinez, Alejandro; Stemmer, Salomon M; Cortot, Alexis B; Barlesi, Fabrice; Quoix, Elisabeth; Burkard, Mark E; Selcuklu, S Duygu; Hunt, Casey; Donoghue, Mark T A; Kris, Mark G; Bebchuk, Judith; Eli, Lisa D; McCulloch, Leanne; Solit, David B; Jänne, Pasi A

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

Tucatinib 和 trastuzumab 治疗 HER2 突变转移性乳腺癌:一项 II 期篮式试验

Okines, Alicia F C; Curigliano, Giuseppe; Mizuno, Nobumasa; Oh, Do-Youn; Rorive, Andree; Soliman, Hatem; Takahashi, Shunji; Bekaii-Saab, Tanios; Burkard, Mark E; Chung, Ki Y; Debruyne, Philip R; Fox, Jenny R; Gambardella, Valentina; Gil-Martin, Marta; Hamilton, Erika P; Monk, Bradley J; Nakamura, Yoshiaki; Nguyen, Danny; O'Malley, David M; Olawaiye, Alexander B; Pothuri, Bhavana; Reck, Martin; Sudo, Kazuki; Sunakawa, Yu; Van Marcke, Cedric; Yu, Evan Y; Ramos, Jorge; Tan, Sherry; Bieda, Mark; Stinchcombe, Thomas E; Pohlmann, Paula R

Correction: Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles

更正:多种靶向微管的抗癌药物通过诱导多极纺锤体上的染色体分离错误来杀死细胞。

Zhou, Amber S; Tucker, John B; Scribano, Christina M; Lynch, Andrew R; Carlsen, Caleb L; Pop-Vicas, Sophia T; Pattaswamy, Srishrika M; Burkard, Mark E; Weaver, Beth A

One step 4× and 12× 3D-ExM enables robust super-resolution microscopy of nanoscale cellular structures.

一步式 4× 和 12× 3D-ExM 可实现对纳米级细胞结构的稳健超分辨率显微成像

Norman Roshan X, Chen Yu-Chia, Recchia Emma E, Loi Jonathan, Rosemarie Quincy, Lesko Sydney L, Patel Smit, Sherer Nathan, Takaku Motoki, Burkard Mark E, Suzuki Aussie

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

CRESTONE:一项评估HER3单克隆抗体Seribantumab治疗伴有Neuregulin-1 (NRG1)融合的实体瘤的疗效和安全性的II期研究

Patil, Tejas; Lin, Jessica J; Cheema, Parneet K; Carrizosa, Daniel R; Burkard, Mark E; Elamin, Yasir Y; Desai, Jayesh; Patel, Jyoti D; Nagasaka, Misako; Reckamp, Karen L; Waqar, Saiama N; Bauman, Jessica R; Schram, Alison M; Gadgeel, Shirish M; Ma, Patrick C; Konduri, Kartik; Nguyen, Danny; Misleh, Jamal; Bleeker, Jonathan; Weiss, Matthias; Thavaneswaran, Subotheni; Haura, Eric B; Deegan, Maegan; Kaufman, Jonathan; Srivastava, Jaya; Jansen, Valerie M; Liu, Stephen V

Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8(+) T Cells in Breast Cancer

基质Versican的积累和蛋白水解调节CD8(+) T细胞在乳腺癌中的浸润

Emmerich, Philip B; Qyli, Tonela; Johnson, Katherine A; Chaudhuri, Somak; Clark, Kristen M; Verhagen, Nathaniel B; Depke, Mitchell G; Clipson, Linda; Pasch, Cheri A; Papadas, Athanasios; Burkard, Mark E; Wisinski, Kari B; McGregor, Stephanie M; Asimakopoulos, Fotis; Deming, Dustin A

Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity.

利用亚克隆反应异质性来定义癌症类器官的治疗敏感性

Kratz Jeremy D, Rehman Shujah, Johnson Katherine A, Gillette Amani A, Sunil Aishwarya, Favreau Peter F, Pasch Cheri A, Miller Devon, Zarling Lucas C, Yeung Austin H, Clipson Linda, Anderson Samantha J, Steimle Alyssa K, Sprackling Carley M, Lemmon Kayla K, Abbott Daniel E, Burkard Mark E, Bassetti Michael F, Eickhoff Jens C, Foley Eugene F, Heise Charles P, Kimple Randall J, Lawson Elise H, LoConte Noelle K, Lubner Sam J, Mulkerin Daniel L, Matkowskyj Kristina A, Sanger Cristina B, Uboha Nataliya V, Mcilwain Sean J, Ong Irene M, Carchman Evie H, Skala Melissa C, Deming Dustin A

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers

一项针对晚期三阴性或BRCA1/2阳性、HER2阴性乳腺癌的I/II期试验,研究gedatolisib联合talazoparib的疗效。

Phadke, Sneha; Miller, Kathy D; Shah, Ami; Danciu, Oana C; Chen, Yi; Yu, Menggang; Burkard, Mark E; Wisinski, Kari B

A survey of chromosomal instability measures across mechanistic models

对不同机制模型中染色体不稳定性指标的调查

Lynch, Andrew R; Bradford, Shermineh; Zhou, Amber S; Oxendine, Kim; Henderson, Les; Horner, Vanessa L; Weaver, Beth A; Burkard, Mark E